Key facts
- This page summarizes Timothy P. Noyes's Form 4 filing for Aerovate Therapeutics, Inc. (JBIO).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 May 2024, 19:10.
Timothy P. Noyes - 16 May 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)
- Reporting relationship
- CHIEF EXECUTIVE OFFICER, Director
- Issuer ticker
- JBIO
- Reported as of
- 16 May 2024
- Net transaction value
- -$194,355
- SEC form
- 4
- Accepted by SEC
- 17 May 2024, 19:10:13 UTC
- Prior SEC filing
- 03 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ George A. Eldridge, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Timothy P. Noyes filed Form 4 for Aerovate Therapeutics, Inc. (JBIO) on 17 May 2024.
Change
- Previous filing in this sequence was filed on 03 May 2024.
- Current net transaction value: -$194,355.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVTE
transaction
Common Stock
Options Exercise
- Transaction value
- $21,400
- Shares
- +10,000
- Change %
- Price
- $2.14*
- Shares after
- 10,000
- Date
- 16 May 2024
- Ownership
- Direct
- Footnotes
- F1
AVTE
transaction
Common Stock
Sale
- Transaction value
- $187,410
- Shares
- -8,707
- Change %
- -87%
- Price
- $21.52
- Shares after
- 1,293
- Date
- 16 May 2024
- Ownership
- Direct
- Footnotes
- F1, F2
AVTE
transaction
Common Stock
Sale
- Transaction value
- $28,345
- Shares
- -1,293
- Change %
- -100%
- Price
- $21.92
- Shares after
- 0
- Date
- 16 May 2024
- Ownership
- Direct
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVTE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -10,000
- Change %
- -2.8%
- Price
- $0.000000
- Shares after
- 343,381
- Date
- 16 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $2.14
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.
Footnote F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.87 to $21.84, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.87 to $22.035, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F4
A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.